PAVmed Inc.
PAVM
|
$1.85
-1.07%
-3.89%
1
|
Health Technology
(0.0% 1d) (-10.2% 1m) (295.0% 1y) (0.0% 2d) (-1.1% 3d) (-0.5% 7d) (-34.79% volume)
Earnings Calendar: 2023-11-14
Market Cap: $ 16,968,812
http://www.pavmed.com
Sec Filling | Patents | 15 employees
PAVmed, Inc. is a medical device company, which develops and commercializes a pipeline of medical products. Its product portfolio includes DisappEAR, PORTIO, Caldus, Carpx, NextCath, and NextFlo. The firm conducts its operations in four divisions: GI Health, Minimally Invasive Interventions, Infusion Therapy and Emerging Innovations. The GI Health division consists of Edouard Esophageal DNA Test, EsoCheck Esophageal Cell Collection Device, and EsoCure Esophageal Ablation Device with Caldus Technology. The Minimally Invasive Interventions division consists of CarpX, which is a patented, single-use disposable, minimally invasive device designed to treat carpal tunnel syndrome. The Infusion Therapy division consists of PortIO, which is a novel, patented, implantable, intraosseous vascular medical device; and NextFlo, which is designed to deliver gravity-driven infusions independent of the height of the IV bag. The Emerging Innovations division refers to a diversified and expanding portfolio of innovative products designed to address unmet clinical needs across a broad range of clinical conditions. The company was founded on June 26, 2014 and is headquartered in New York, NY.
t-cell ceiling
add to watch list Paper trade email alert is off
Press-releases
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Published: 2024-04-08 (Crawled : 13:30) - biospace.com/
LUCD | $0.6831 -5.52% -5.32% 820
|
|
| O: -0.87%
H: 0.55%
C: -2.14%
PAVM | $1.85 -1.07% -3.89% 1
|
Health Technology
|
| O: -1.36%
H: 1.38%
C: -0.92%
conference diagnostics
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-26 (Crawled : 00:00) - prnewswire.com
LUCD | $0.6831 -5.52% -5.32% 820
|
|
| O: 0.0%
H: 2.02%
C: 0.0%
PAVM | $1.85 -1.07% -3.89% 1
|
Health Technology
|
| O: 12.62%
H: 21.98%
C: 16.16%
business year update financial results
Lucid Diagnostics Provides Business Update and Preliminary Fourth Quarter and Full Year 2023 Financial Results
Published: 2024-03-25 (Crawled : 22:00) - prnewswire.com
LUCD | $0.6831 -5.52% -5.32% 820
|
|
| O: -4.72%
H: 4.95%
C: -1.98%
PAVM | $1.85 -1.07% -3.89% 1
|
Health Technology
|
| O: -1.81%
H: 2.43%
C: -5.07%
business year update diagnostics financial results
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population
Published: 2024-03-21 (Crawled : 20:00) - biospace.com/
LUCD | $0.6831 -5.52% -5.32% 820
|
|
| O: -0.9%
H: 8.18%
C: 0.91%
PAVM | $1.85 -1.07% -3.89% 1
|
Health Technology
|
| O: 0.45%
H: 5.41%
C: -4.5%
esoguard first positive diagnostics study
Lucid Diagnostics Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference
Published: 2024-03-20 (Crawled : 14:00) - biospace.com/
LUCD | $0.6831 -5.52% -5.32% 820
|
|
| O: -0.93%
H: 3.74%
C: 3.74%
PAVM | $1.85 -1.07% -3.89% 1
|
Health Technology
|
| O: 1.95%
H: 14.83%
C: 5.74%
conference disease week diagnostics
PAVmed to Hold a Business Update Conference Call and Webcast on March 27, 2024
Published: 2024-03-13 (Crawled : 14:30) - biospace.com/
PAVM | $1.85 -1.07% -3.89% 1
|
Health Technology
|
| O: -2.0%
H: 0.41%
C: -11.84%
conference business update
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
Published: 2024-02-16 (Crawled : 22:00) - prnewswire.com
PAVM | $1.85 -1.07% -3.89% 1
|
Health Technology
| Email alert
Add to watchlist
LUCD | $0.6831 -5.52% -5.32% 820
|
| Email alert
Add to watchlist
health world update program diagnostics
Lucid Diagnostics Chairman & CEO, Dr. Lishan Aklog, Highlights EsoCheck® Esophageal Cell Collection Device during Congressional Testimony
Published: 2024-02-15 (Crawled : 14:00) - biospace.com/
LUCD | $0.6831 -5.52% -5.32% 820
|
|
| O: 4.48%
H: 0.0%
C: -2.14%
PAVM | $1.85 -1.07% -3.89% 1
|
Health Technology
|
| O: 0.51%
H: 5.01%
C: -2.01%
esocheck device cell diagnostics
Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
Published: 2024-02-08 (Crawled : 13:30) - biospace.com/
LUCD | $0.6831 -5.52% -5.32% 820
|
|
| O: 0.0%
H: 1.44%
C: -3.79%
PAVM | $1.85 -1.07% -3.89% 1
|
Health Technology
|
| O: 4.02%
H: 2.21%
C: -7.18%
esoguard contract diagnostics
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
Published: 2023-12-12 (Crawled : 14:00) - biospace.com/
LUCD | $0.6831 -5.52% -5.32% 820
|
|
| O: 2.19%
H: 2.71%
C: -2.86%
PAVM | $1.85 -1.07% -3.89% 1
|
Health Technology
|
| O: 0.0%
H: 32.9%
C: 24.84%
positive publication diagnostics results
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0001062993-24-004288 | 4 | 2024-02-23 | 2024-02-22 | Buy | A | 65000 | 65000 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 50% | 50% |
Top 10 Gainers
CSSE 4 | $0.299 96.32% 7M
|
Consumer Services
BRFH 4 | $1.99 80.91% 13M
|
Manufacturing
BOF | $1.915 63.68% 620K
|
AMST | $3.13 56.5% 500K
|
Technology Services
ACON | $0.3595 24.83% 3.5M
|
n/a
ILAG | $0.669 23.89% 13M
|
CDTX | News | $14.57 18.55% 330K
|
Health Technology
ULBI M | $10.12 15.92% 120K
|
Producer Manufacturing
LRHC | $1.79 11.88% 3K
|
n/a
AIXI | $1.34 8.94% 42K
|
n/a
Last 48 Hours Insiders Buying
MNSB P 1470 | $15.89 -2.87% -3.02% 0
|
Finance
|
12:00
RKT P 347 | $12.55 -0.63% 0.88% 0
|
Finance
|
22:30
NWFL | News | $24.21 0.42% 1.99% 0
|
Finance
|
22:00
TGEN P 10000 | $0.68 20K
|
Utilities
|
20:01
RMCF | $3.55 0.28% 0.28% 0
|
Consumer Non-Durables
|
20:10